0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
China Achondroplasia Treatment Market Report & Forecast 2021-2027
Published Date: August 2021
|
Report Code: QYRE-Auto-38Y277
Home | Market Reports | Health | Health Conditions | Genetic Disorders
China Achondroplasia Treatment Market Report Forecast 2021 2027

China Achondroplasia Treatment Market Report & Forecast 2021-2027

Code: QYRE-Auto-38Y277
Report
August 2021
93 Pages
QYResearch
Region: Global, Europe, Japan, India, North America, Southeast Asia, China,
Description
Table of Content
Tables & Figures
China Achondroplasia Treatment Market, By Type, 2016-2021, 2022-2027 ($ Millions)
China Achondroplasia Treatment Market Segment Percentages, By Type, 2020 (%)
CNP Analogue
Ligand Trap
TKI
Others
China Achondroplasia Treatment Market, By Application, 2016-2021, 2022-2027 ($ Millions)
China Achondroplasia Treatment Market Segment Percentages, By Application, 2020 (%)
Hospital
Retail Pharmacy
Others
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Achondroplasia Treatment revenues in China market, 2016-2021 (Estimated), ($ millions)
Key companies Achondroplasia Treatment revenues share in China market, 2020 (%)

Further, the report presents profiles of competitors in the market, key players include:

Ascendis Pharma
BioMarin
Ribomic
QED Therapeutics
Pfizer
Astellas
1 Introduction to Research & Analysis Reports
1.1 Achondroplasia Treatment Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 China Achondroplasia Treatment Market Overview
1.4 Methodology & Sources of Information
1.4.1 Research Methodology
1.4.2 Research Process
1.4.3 Base Year
2 China Achondroplasia Treatment Overall Market Size
2.1 China Achondroplasia Treatment Market Size: 2021 VS 2027
2.2 China Achondroplasia Treatment Revenue, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Achondroplasia Treatment Players in China Market
3.2 Top China Achondroplasia Treatment Companies Ranked by Revenue
3.3 China Achondroplasia Treatment Revenue by Companies
3.4 Top 3 and Top 5 Achondroplasia Treatment Companies in China Market, by Revenue in 2020
3.5 Companies Achondroplasia Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Achondroplasia Treatment Players in China Market
3.6.1 List of Tier 1 Achondroplasia Treatment Companies in China
3.6.2 List of Tier 2 and Tier 3 Achondroplasia Treatment Companies in China
4 Sights by Type
4.1 Overview
4.1.1 By Type - China Achondroplasia Treatment Market Size Markets, 2021 & 2027
4.1.2 CNP Analogue
4.1.3 Ligand Trap
4.1.4 TKI
4.1.5 Others
4.2 By Type - China Achondroplasia Treatment Revenue & Forecasts
4.2.1 By Type - China Achondroplasia Treatment Revenue, 2016-2021
4.2.2 By Type - China Achondroplasia Treatment Revenue, 2022-2027
4.2.3 By Type - China Achondroplasia Treatment Revenue Market Share, 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application - China Achondroplasia Treatment Market Size, 2021 & 2027
5.1.2 Hospital
5.1.3 Retail Pharmacy
5.1.4 Others
5.2 By Application - China Achondroplasia Treatment Revenue & Forecasts
5.2.1 By Application - China Achondroplasia Treatment Revenue, 2016-2021
5.2.2 By Application - China Achondroplasia Treatment Revenue, 2022-2027
5.2.3 By Application - China Achondroplasia Treatment Revenue Market Share, 2016-2027
6 Achondroplasia Treatment Companies Profiles
6.1 Ascendis Pharma
6.1.1 Ascendis Pharma Company Details
6.1.2 Ascendis Pharma Business Overview
6.1.3 Ascendis Pharma Achondroplasia Treatment Introduction
6.1.4 Ascendis Pharma Achondroplasia Treatment Revenue in China Market (2016-2021)
6.1.5 Ascendis Pharma Recent Developments
6.2 BioMarin
6.2.1 BioMarin Company Details
6.2.2 BioMarin Business Overview
6.2.3 BioMarin Achondroplasia Treatment Introduction
6.2.4 BioMarin Achondroplasia Treatment Revenue in China Market (2016-2021)
6.2.5 BioMarin Recent Developments
6.3 Ribomic
6.3.1 Ribomic Company Details
6.3.2 Ribomic Business Overview
6.3.3 Ribomic Achondroplasia Treatment Introduction
6.3.4 Ribomic Achondroplasia Treatment Revenue in China Market (2016-2021)
6.3.5 Ribomic Recent Developments
6.4 QED Therapeutics
6.4.1 QED Therapeutics Company Details
6.4.2 QED Therapeutics Business Overview
6.4.3 QED Therapeutics Achondroplasia Treatment Introduction
6.4.4 QED Therapeutics Achondroplasia Treatment Revenue in China Market (2016-2021)
6.4.5 QED Therapeutics Recent Developments
6.5 Pfizer
6.5.1 Pfizer Company Details
6.5.2 Pfizer Business Overview
6.5.3 Pfizer Achondroplasia Treatment Introduction
6.5.4 Pfizer Achondroplasia Treatment Revenue in China Market (2016-2021)
6.5.5 Pfizer Recent Developments
6.6 Astellas
6.6.1 Astellas Company Details
6.6.2 Astellas Business Overview
6.6.3 Astellas Achondroplasia Treatment Introduction
6.6.4 Astellas Achondroplasia Treatment Revenue in China Market (2016-2021)
6.6.5 Astellas Recent Developments
7 Conclusion
8 Appendix
8.1 Note
8.2 Examples of Clients
8.3 Author Details
8.4 Disclaimer
List of Tables
    Table 1. Achondroplasia Treatment Market Opportunities & Trends in China Market
    Table 2. Achondroplasia Treatment Market Drivers in China Market
    Table 3. Achondroplasia Treatment Market Restraints in China Market
    Table 4. Key Players of Achondroplasia Treatment in China Market
    Table 5. Top Achondroplasia Treatment Players in China Market, Ranking by Revenue (2019)
    Table 6. China Achondroplasia Treatment Revenue by Companies, (US$, Mn), 2016-2021
    Table 7. China Achondroplasia Treatment Revenue Share by Companies, 2016-2021
    Table 8. Companies Achondroplasia Treatment Product Type
    Table 9. List of Tier 1 Achondroplasia Treatment Companies, Revenue (US$, Mn) in 2020 and Market Share
    Table 10. List of Tier 2 and Tier 3 Achondroplasia Treatment Companies, Revenue (US$, Mn) in 2020 and Market Share
    Table 11. By Type – China Achondroplasia Treatment Revenue, (US$, Mn), 2021 & 2027
    Table 12. By Type - China Achondroplasia Treatment Revenue (US$, Mn), 2016-2021
    Table 13. By Type - China Achondroplasia Treatment Revenue (US$, Mn), 2022-2027
    Table 14. By Application – China Achondroplasia Treatment Revenue, (US$, Mn), 2021 VS 2027
    Table 15. By Application - China Achondroplasia Treatment Revenue (US$, Mn), 2016-2021
    Table 16. By Application - China Achondroplasia Treatment Revenue (US$, Mn), 2022-2027
    Table 17. Ascendis Pharma Company Details
    Table 18. Ascendis Pharma Business Overview
    Table 19. Ascendis Pharma Achondroplasia Treatment Product
    Table 20. Ascendis Pharma Achondroplasia Treatment Revenue in China Market (2016-2021) & (US$ Million)
    Table 21. Ascendis Pharma Recent Developments
    Table 22. BioMarin Company Details
    Table 23. BioMarin Business Overview
    Table 24. BioMarin Achondroplasia Treatment Product
    Table 25. BioMarin Achondroplasia Treatment Revenue in China Market (2016-2021) & (US$ Million)
    Table 26. BioMarin Recent Developments
    Table 27. Ribomic Company Details
    Table 28. Ribomic Business Overview
    Table 29. Ribomic Achondroplasia Treatment Product
    Table 30. Ribomic Achondroplasia Treatment Revenue in China Market (2016-2021) & (US$ Million)
    Table 31. Ribomic Recent Developments
    Table 32. QED Therapeutics Company Details
    Table 33. QED Therapeutics Business Overview
    Table 34. QED Therapeutics Achondroplasia Treatment Product
    Table 35. QED Therapeutics Achondroplasia Treatment Revenue in China Market (2016-2021) & (US$ Million)
    Table 36. QED Therapeutics Recent Developments
    Table 37. Pfizer Company Details
    Table 38. Pfizer Business Overview
    Table 39. Pfizer Achondroplasia Treatment Product
    Table 40. Pfizer Achondroplasia Treatment Revenue in China Market (2016-2021) & (US$ Million)
    Table 41. Pfizer Recent Developments
    Table 42. Astellas Company Details
    Table 43. Astellas Business Overview
    Table 44. Astellas Achondroplasia Treatment Product
    Table 45. Astellas Achondroplasia Treatment Revenue in China Market (2016-2021) & (US$ Million)
    Table 46. Astellas Recent Developments
List of Figures
    Figure 1. Achondroplasia Treatment Segment by Type
    Figure 2. Achondroplasia Treatment Segment by Application
    Figure 3. China Achondroplasia Treatment Market Overview: 2020
    Figure 4. China Achondroplasia Treatment Market Size: 2021 VS 2027 (US$, Mn)
    Figure 5. China Achondroplasia Treatment Revenue, 2016-2027 (US$, Mn)
    Figure 6. The Top 3 and 5 Players Market Share by Achondroplasia Treatment Revenue in 2020
    Figure 7. By Type - China Achondroplasia Treatment Revenue Market Share, 2016-2027
    Figure 8. By Application - China Achondroplasia Treatment Revenue Market Share, 2016-2027
    Figure 9. Ascendis Pharma Achondroplasia Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
    Figure 10. BioMarin Achondroplasia Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
    Figure 11. Ribomic Achondroplasia Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
    Figure 12. QED Therapeutics Achondroplasia Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
    Figure 13. Pfizer Achondroplasia Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
    Figure 14. Astellas Achondroplasia Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
SELECT A FORMAT
Added to Cart

Electronic (PDF)
$3400
This license allows only one user(purchaser of the report) to access the PDF.

Electronic (PDF)
$5100
This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Electronic (PDF)
$6800
This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Seventh Sense AI